British Journal of Cancer

FIGURES AND TABLES

FROM:

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)

B Nilsson, K Sjölund, L-G Kindblom, J M Meis-Kindblom, P Bümming, O Nilsson, J Andersson and H Ahlman

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 1.

Kaplan–Meier estimates of recurrence-free survival in patients with high-risk GIST. Historical controls (black) were only treated with R0 resection (mean follow-up 36 months, range 2–151 months), while the consecutive series of patients (mean follow-up 40 months, range 18–62 months) had adjuvant imatinib (400 mg day-1) for 1 year after radical surgery (red). In the latter group only one patient has developed recurrence.

Full figure and legend (54K)
Table 1 - Clinical data and tumour characteristics - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 1 - Clinical data and tumour characteristics.

Full table
BACK TO ARTICLE